Tisento Therapeutics today announced that the global Phase 2b PRIZM study is fully enrolled. PRIZM is evaluating zagociguat - a once-daily, oral investigational medicine - as a treatment for the rare ...
VarmX and Rentschler Biopharma partner to advance novel coagulation therapy toward Phase 3 and commercialization ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback